Markets
U.S. President Trump Meets With Japanese Business Leaders In Tokyo
US President Donald Trump shakes hands with Apple CEO Tim Cook at the US Ambassador’s Residence in Tokyo, Japan (Andrew Harnik/Getty Images)

Apple and Nvidia are showing how China failures are no barrier to unparalleled stock market success

China-exposed companies are crushing the S&P 500 this year. That’s because “China-exposed company” is just another term for “high-growth company.”

Luke Kawa

Nvidia and Apple are the two most valuable publicly traded companies in the world. 

One big thing the two tech behemoths have in common: they’ve ascended to those lofty heights despite their China businesses being in the penalty box this year.

Tariffs have weighed on Apple’s operations and its sales in Greater China are down year on year in eight of its last nine quarters. Nvidia has been effectively shut out of China’s AI market for much of the year due to export restrictions.

And yet...

Apple’s latest earnings report propelled the company to hitherto unseen heights despite sales in Greater China coming in at $14.5 billion, 11.8% shy of estimates and down 3.6% year on year.

Today, Nvidia CEO Jensen Huang said he doesn’t know if he’ll ever be able to sell Blackwell chips to China. But that hasn’t stopped the chip designer from booking more than $500 billion in orders for its Blackwell and Rubin AI GPUs through next year.

The state of the US economy and markets in 2025:

Success, despite a lack of ability to boost sales in the world’s second-largest economy, tells us two very different things about these two market leaders.

For Apple, it speaks to its moat, brand, and platform, which enable Services revenues to continue to climb.

Even if the iPhone upgrade cycle is less about how good the new phones are and more about how old customers’ existing phones are — iPhone buyers are a loyal bunch.

Update for Apple’s Q1 guidance: I upgraded to the iPhone 17 Pro yesterday to stay in the blue bubble gang. Even as a relative luddite, getting one new piece of Apple hardware every couple years, that’s still meant my monthly bill for its services — Apple Music and iCloud, mainly — has trended higher.

In short, Apple is a reminder of how robust the megacap tech titans’ businesses are before we even think about any returns from their aggressive AI build-outs.

On the other hand, Nvidia is all about that AI boost — which has been meaningfully accelerated by the hundred of billions that most megacap tech leaders (Apple, ironically, being a notable exception) are eager to spend to develop and implement this new technology. And they’re able to do that because of how strong their existing businesses are!

These ascensions to $4 trillion (and beyond!) market caps in spite of China challenges isn’t just an Apple and Nvidia story, but rather is broadly reflected in the performance of most US stocks that have elevated sales exposure to the world’s second-largest economy.

A Goldman Sachs basket of Russell 1000 companies with elevated sales exposure to China (excluding the semiconductor industry) has outperformed that benchmark meaningfully year to date.

And semiconductors, which are excluded from that aforementioned basket because they’d otherwise dominate it, are doing even better.

These firms, in spite of elevated trade tensions and tariff levels between the US and China, have seen forward earnings estimates climb by far more than the average large-cap US stocks this year. These days, a “China-exposed” company is just a “high-growth” company by another name.

More Markets

See all Markets
markets

FuelCell Energy rises as AI data center pipeline overshadows Q2 miss

FuelCell Energy shares rebounded into positive territory during premarket trading, reversing an initial dip sparked by Q2 results that showed widening net losses and a year-over-year revenue decline.

Key numbers:

  • Revenue of $35.6 million (compared to analyst estimates of $40.56 million).

  • An adjusted loss per share of $1.45 (estimate: a $0.50 loss).

That revenue number marks a 5% decrease from the $37.4 million generated during the same quarter last year.

The company’s net loss expanded to $78.7 million, or $1.45 per share, compared to a loss of $38.8 million in the prior-year period. Management attributed the deeper loss primarily to a $42.6 million one-time impairment expense linked to essential equipment upgrades at its Groton Project facility.

While a 9.9% drop in total backlog initially added to the shares’ downward momentum, investors appeared to quickly pivot their attention to the company’s forward-looking metrics. FuelCell highlighted a 267% sequential jump in its sales pipeline, which has reached 4 gigawatts. The surge is driven by demand for its packaged 12.5-megawatt utility-grade power block solution tailored specifically for the booming AI data center market.

To support this high-growth data center strategy, FuelCell announced a major capacity expansion at its Torrington, Connecticut, manufacturing facility. The company plans to raise its annualized production ceiling from 350 MW to 500 MW, an infrastructure upgrade estimated to cost between $200 million and $275 million over the next 24 months.

Driven by the AI data center narrative, FuelCell Energy’s stock has risen over 130% year to date.

markets

Lilly says its next-gen GLP-1 shot drove 28.3% weight loss, reduced comorbidities

Eli Lilly has risen around 4% in premarket trading after reporting impressive trial results for its next-generation weight-loss drug over the weekend.

According to the results unveiled on Saturday, Lilly’s experimental weight-loss shot, retatrutide, helped patients lose 28.3% of their body weight at 80 weeks. That’s more than tirzepatide, Lilly’s weight-loss shot currently considered the most effective in the market, which helped people lose 26% of their weight over 88 weeks.

Retatrutide is a triple agonist, meaning it mimics three different hormones that promote weight loss, compared to one by Novo Nordisk’s semaglutide and two by tirzepatide. Lilly says it helps preserve more muscle mass than other weight-loss shots and also helped improve knee osteoarthritis pain and obstructive sleep apnea.

Lilly has said it would submit the drug for approval this year with the goal of getting it out to market in 2027. The jab could be the next big moneymaker for Lilly, which currently sells the most lucrative drug in the world but has had an underwhelming rollout of its oral weight-loss pill, which came to market earlier this year.

Retatrutide is already quite popular among those who experiment with peptides, or unapproved injectable drugs often sold online “for research purposes only.” For gym bros trying to attain a certain physique, a drug that has shown it can melt fat while preserving muscle is enticing.

But in a market full of knockoff drugs, will retatrutide enthusiasts pay full price for the drug when it officially goes to market?

markets

Marvell and Flex rise on S&P 500 inclusion announcement

Chipmaker Marvell Technology and electronics manufacturer Flex are jumping 7% and 3%, respectively, in premarket trading on Monday after S&P Dow Jones Indices announced late on Friday that the two companies are set to join the S&P 500 benchmark index.

Replacing Pool Corp. and Campbell’s in the S&P 500, Marvell and Flex’s addition will be effective from June 22, per a press release from the provider, which assesses and updates the index on a quarterly basis.

Marvell has been one of the leading candidates for inclusion across the last few quarterly index rebalances. The company has ballooned into a $230 billion chip giant of late, thanks to the wider AI boom, investors chasing momentum, and, yes, Jensen Huang. Flex, which has been part of the S&P MidCap 400 Index since 2024, has also grown recently, having played a part in the data center boom with a portfolio that spans across infrastructure and cooling systems.

With today’s premarket movement taken into account, MRVL has now risen almost 40% in the last week alone.

Dickens, Great Expectations, He said, Aha! would you?

Tech tumbles as momentum stocks run into a blowout jobs report and a wave of profit-taking

The AI trade is under some pressure, taking prices back like... a few days. President Donald Trump is not a fan of the price action.

Latest Stories

Sherwood Media, LLC and Chartr Limited produce fresh and unique perspectives on topical financial news and are fully owned subsidiaries of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Money, LLC, Robinhood U.K. Ltd, Robinhood Derivatives, LLC, Robinhood Gold, LLC, Robinhood Asset Management, LLC, Robinhood Credit, Inc., Robinhood Ventures DE, LLC and, where applicable, its managed investment vehicles.